how glp-1 agonists work Receptor as Treatments for Type 2 Diabetes How do GLP-1 Agonists Work?

The year delivered progress across clinical evidence, policy, and changing market dimensions, reinforcing obesity as a chronic disease requiring structured, long-term management

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.

Learn how employers can manage GLP-1 costs with strategies that balance affordability and access.

Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022